focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 11,850.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 620.00 (5.232%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2020 16:00

RNS Number : 3749L
AstraZeneca PLC
29 April 2020
 

29 April 2020 16:00 BST

 

Results of Annual General Meeting held on 29 April 2020

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019

 

1,061,180,101

99.92

872,215

0.08

1,062,052,316

80.93%

7,121,452

2

To confirm dividends

 

1,058,995,786

99.10

9,598,531

0.90

1,068,594,317

81.43%

579,469

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,068,300,235

99.97

312,449

0.03

1,068,612,684

81.43%

560,776

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,067,398,628

99.90

1,086,858

0.10

1,068,485,486

81.42%

687,961

5a

To re-elect Leif Johansson as a Director

 

1,065,113,167

99.69

3,276,071

0.31

1,068,389,238

81.42%

784,805

5b

To re-elect Pascal Soriot as a Director

 

1,067,248,723

99.90

1,033,124

0.10

1,068,281,847

81.41%

892,364

5c

To re-elect Marc Dunoyer as a Director

 

1,060,164,242

99.25

8,056,265

0.75

1,068,220,507

81.40%

952,979

5d

To re-elect Geneviève Berger as a Director

 

882,846,920

83.06

179,994,848

16.94

1,062,841,768

80.99%

6,331,650

5e

To re-elect Philip Broadley as a Director

 

1,066,048,992

99.79

2,190,705

0.21

1,068,239,697

81.41%

933,713

5f

To re-elect Graham Chipchase as a Director

 

1,062,682,507

99.48

5,520,936

0.52

1,068,203,443

81.40%

969,967

5g

To elect Michel Demaré as a Director

 

1,066,252,259

99.82

1,969,593

0.18

1,068,221,852

81.40%

951,558

5h

To re-elect Deborah DiSanzo as a Director

 

1,067,836,362

99.97

351,091

0.03

1,068,187,453

81.40%

985,957

5i

To re-elect Sheri McCoy as a Director

 

1,064,329,862

99.64

3,890,368

0.36

1,068,220,230

81.40%

951,792

5j

To re-elect Tony Mok as a Director

1,067,117,370

99.90

1,066,669

0.10

1,068,184,039

81.40%

989,371

5k

To re-elect Nazneen Rahman as a Director

 

1,067,376,963

99.92

821,467

0.08

1,068,198,430

81.40%

973,592

5l

To re-elect Marcus Wallenberg as a Director

 

955,082,665

89.42

113,060,725

10.58

1,068,143,390

81.40%

1,030,019

6

To approve the Annual Report on Remuneration for the year ended 31 December 2019

 

1,032,308,145

96.65

35,747,783

3.35

1,068,055,928

81.39%

1,118,038

7

To approve the Directors' Remuneration Policy

 

972,774,742

94.71

54,292,376

5.29

1,027,067,118

78.27%

42,106,679

8

To authorise limited political donations

 

1,038,907,152

97.75

23,872,400

2.25

1,062,779,552

80.99%

6,394,668

9

To authorise the Directors to allot shares

 

910,654,650

85.26

157,472,093

14.74

1,068,126,743

81.40%

1,046,979

10

To authorise the Directors to disapply pre-emption rights

 

1,058,066,972

99.23

8,200,338

0.77

1,066,267,310

81.26%

2,906,339

11

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

1,054,711,677

98.92

11,513,414

1.08

1,066,225,091

81.25%

2,948,557

12

To authorise the Company to purchase its own shares

 

1,051,131,060

98.41

16,950,800

1.59

1,068,081,860

81.39%

1,091,896

13

To reduce the notice period for general meetings

 

998,062,805

93.44

70,101,553

6.56

1,068,164,358

81.40%

1,008,865

14

To approve the 2020 Performance Share Plan

1,010,149,491

95.66

45,877,396

4.34

1,056,026,887

80.48%

13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPPURCCUPUGCB
Date   Source Headline
21st Sep 20227:00 amRNSTezspire approved in the EU for severe asthma
20th Sep 20227:00 amRNSEvusheld approved in EU for COVID-19 treatment
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.